Printer Friendly

APPLIED BIOSCIENCE INTERNATIONAL FILES REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION

 APPLIED BIOSCIENCE INTERNATIONAL FILES REGISTRATION STATEMENT
 WITH THE SECURITIES AND EXCHANGE COMMISSION
 EAST MILLSTONE, N.J., May 5 /PRNewswire/ -- Applied Bioscience International Inc. (NASDAQ: APBI) announced today that it had filed a registration statement with the Securities and Exchange Commission covering 4,500,000 shares, 1,200,000 of which are to be sold by the company and 3,300,000 shares by selling stockholders.
 The company said that the proceeds of the company's offering would be used to reduce long-term and short-term indebtedness, for general corporate purposes and for possible future acquisitions.
 The shares are to be offered through underwriters led by Lehman Brothers, Hambrecht & Quist Incorporated, Kemper Securities Group, Inc. and Raymond James & Associates, Inc.
 Applied Bioscience provides a broad range of inter-related services including, through its Life Sciences Group, biological safety testing and clinical research and development and, through its Environmental Sciences Group, assessment and management of chemical and environmental risk, agrochemical research and development, and related analytical chemistry services. These services are provided under contract to clients in the pharmaceutical, general chemical, agrochemical, biotechnology and other industries throughout the world.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 A copy of the offering prospectus may be obtained from the Prospectus Department of Lehman Brothers, 250 West St., New York, NY 10013.
 -0- 5/5/92
 /CONTACT: John H. Timoney, vice president and CFO of Applied Bioscience, 908-873-2550; or John McNamara, president of John McNamara Advertising, 212-509-7779, for Applied Bioscience/
 (APBI) CO: Applied Bioscience International, Inc. ST: New Jersey IN: MTC SU: OFR


GK-AH -- NY056 -- 6542 05/05/92 11:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:354
Previous Article:$560,000 IN LOANS/GRANT TO BENEFIT EIGHT CLEVELAND BUSINESSES AND CREATE NEW HOUSING UNITS IN THE CITY'S WAREHOUSE DISTRICT
Next Article:STEINMULLER ACQUIRES MINORITY INTEREST IN TAMPELLA POWER


Related Articles
DR PEPPER/SEVEN-UP COMPANIES FILES AMENDMENT TO REGISTRATION STATEMENT
AEI FILES FOR CONVERTIBLE DEBENTURE OFFERING
ZENECA GROUP ANNOUNCES RIGHTS OFFERING
SANTA FE PACIFIC GOLD CORP. FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
CERIDIAN FILES SHELF REGISTRATION STATEMENT; SHARES WOULD BE AVAILABLE FOR FUTURE ACQUISITIONS
METEOR INDUSTRIES, INC. ANNOUNCES FILING OF FORM 10 REGISTRATION STATEMENT
Public Offering of the American Depositary Shares of Multicanal Participacoes S.A.
NAMCO Announces Proposed Common Stock Offering
LION Bioscience Launches Initial Public Offering Listing on Nasdaq and Neuer Markt.
Cypress Bioscience, Inc. Announces Pricing Of Common Stock In Public Offering.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters